only with
Healthcare
Small-cap - With a market cap of ₹86.16 Cr.
| EX-Date | Purpose |
|---|---|
| 06 02 2025 | Quarterly Results |
| 26 05 2025 | Audited Results & Quarterly Results |
| 08 08 2025 | Quarterly Results |
| 08 08 2025 | Quarterly Results |
| 13 11 2025 | Quarterly Results |
| 13 02 2026 | Quarterly Results |
News
Akums Drugs gets European GMP certificates for two facilities in Uttarakhand
These accreditations will enable the company to cater to EU regulated markets
Akums Drugs incorporates wholly owned subsidiary in Europe
The company has incorporated Wholly Owned Subsidiary namely ‘Akums Healthcare Malta’
Akums Drugs incorporates joint venture company in Zambia
The company had executed a Framework Agreement on August 22, 2025 with Government of the Republic of Zambia to establish a local manufacturing facility in Zambia
Akums Drugs executes framework agreement with Government of the Republic of Zambia
The facility, in the future, also plans to export to neighboring countries including, but not limited to, Zimbabwe, Namibia, Botswana, Malawi, Tanzania, Mozambique etc
Akums Drugs and Pharmaceuticals reports consolidated net profit of Rs 75.14 crore in Q4
The total consolidated income of the company increased by 12.43% at Rs 1073.09 crore for Q4FY25
Akums Drugs secures patent for ’Benzalkonium Chloride-Free Brinzolamide Ophthalmic Formulation’
The patent is valid for a term of 20 years
Akums Drugs and Pharmaceuticals reports 66% drop in Q3 consolidated net profit
Total consolidated income of the company decreased by 6.12% at Rs 1024.97 crore for Q3FY25
Akums Drugs enters into agreement for manufacture, supply of selected pharmaceutical formulations
This is in line with Akums growth objective of expanding in European and other regulated markets
Akums Drugs’ arm collaborates with Jagdale Industries
This collaboration exclusively focuses on aseptic manufacturing and subsequent filling in carton packing for the RTD market
Akums Drugs enters into exclusive Master Sales Agreement with Caregen
Akums has been granted the exclusive rights to sell certain Caregen products range, in India, during the term of the agreement
Akums Drugs and Pharmaceuticals enters into MoU with Government of Republic of Zambia
The company has entered into MoU for Local Manufacturing of Medicines
Akums Drugs & Pharmaceuticals enters into license & distribution agreement with Triple Hair Inc
As per the terms of the agreement, Company has been granted the exclusive rights to further develop and market the products recently innovated by Triple Hair Inc, in the Territory of India
Akums Drugs launches new product Famotidine, Calcium Carbonate and Magnesium Hydroxide
This product launch marks a step in commitment to innovation and providing high-quality healthcare solutions to the company’s customers
Akums Drugs gets patent certificate from Government of India
The company has received Patent Certificate on September 12, 2024, for its invention titled ‘Room Stable Hydroxyurea Oral Suspension’
Akums Drugs and Pharmaceuticals files DRHP with SEBI
The company is looking to raise Rs 136 crore through a pre-IPO placement
